Granules

Innovative drug delivery formats designed to support convenience, ease of use and patient-centric care.

Expertise in azido and nitroso impurity characterization, supporting comprehensive quality and analytical requirements for pharmaceutical development.

A broad capsule portfolio combining quality, consistency and reliable pharmaceutical manufacturing.

Comprehensive carbohydrate chemistry capabilities supported by experienced teams and a strong focus on quality and scalability.

Specialized depot injection capabilities supporting long-acting therapeutic solutions.

Dedicated capabilities for genotoxic impurity characterization, supporting pharmaceutical partners in their quality and development requirements.

Specialized expertise in heterocyclic chemistry, supporting a broad range of pharmaceutical molecules and development needs.

Growing capabilities in hormone products, supported by strong pharmaceutical expertise, quality-focused processes and reliable supply for global partners.

Specialized metal chemistry capabilities combining chemistry expertise, quality and a strong focus on dependable solutions for pharmaceutical partners.

A growing ophthalmic portfolio offering quality-focused solutions across diverse therapeutic requirements.

A diverse range of oral solutions designed for flexible and patient-friendly administration.

Quality-focused oral suspension formulations supporting diverse therapeutic applications and patient needs.

MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 24 state-of-the-art manufacturing facilities (16 API and 8 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly.